Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
Recruiting
N/A
Interventional Study
Triple Negative Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Female
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 115 (estimated)
- Sponsor
- Centre Henri Becquerel · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, wit…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Signed informed consent
* Patient with histologically proven TNBC
* Indication for neo-adjuvant chemo-immunotherapy treatment
* Age between 18 and 75
* Affiliated or beneficiary of a social protection scheme
Exclusion Criteria:
* Pregnant or breast-feeding women
* Contraindi…
Contacts